Elevance (ELV) PT Lowered to $478 at RBC Capital

Elevance (ELV) PT Lowered to $515 at Leerink Partners

Leerink Partners analyst Whit Mayo lowered the price target on Elevance (NYSE: ELV) to $515.00 (from $620.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: Reiterate Outperform Rating. 3Q results brought forth a material acceleration of pressures within Medicaid as a result of... More

Elevance (ELV) PT Lowered to $520 at Truist Securities

(Updated - October 18, 2024 7:04 AM EDT)

Truist Securities analyst David MacDonald lowered the price target on Elevance (NYSE: ELV) to $520.00 (from $620.00) while maintaining a Buy rating.

The analyst commented: "We reiterate our Buy rating on ELV. While 3Q results... More

Elevance (ELV) PT Lowered to $555 at UBS

UBS analyst AJ Rice lowered the price target on Elevance (NYSE: ELV) to $555.00 (from $605.00) while maintaining a Buy rating.... More

Increasing unusual put option volume: ELV LAC CNC MGNI FITB WEN EOSE EWW ASHR OKLO

Increasing unusual put option volume: ELV LAC CNC MGNI FITB WEN EOSE EWW ASHR OKLO

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.37%

Investing.com U.S. stocks were mixed after the close on Thursday, as gains in the Oil&Gas, Basic Materials and Financials sectors led shares higher while losses in the Utilities, Healthcare and Consumer Goods sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average rose 0.37% to hit a new all time high, while the S&P 500 index fell 0.02%, and the NASDAQ Composite index added 0.04%.

The best performers of the session on the Dow Jones Industrial Average were Travelers Companies (NYSE: TRV), which rose 9.00% or 21.87 points to... More

Elevance Health Inc. (ELV) Misses Q3 EPS by $1.29, Beats on Revenue

Elevance Health Inc. (NYSE: ELV) reported Q3 EPS of $8.37, $1.29 worse than the analyst estimate of $9.66. Revenue for the quarter came in at $44.7 billion versus the consensus estimate of $43.46 billion.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

Elevance Health (ELV) call put ratio 1 call to 1.9 puts into quarter results

Elevance Health (NYSE: ELV) October call option implied volatility is at 112, November is at 34; compared to its 52-week range of 12 to 36 into the expected release before the bell on October 17. Call put ratio 1 call to 1.9 puts.

Baird Reiterates Outperform Rating on Elevance (ELV)

Baird analyst Michael Ha reiterated an Outperform rating and $625.00 price target on Elevance (NYSE: ELV).

The analyst commented: "Given today's UNH 3Q24 earnings (~80bps MLR miss), we look at the potential read-through to ELV 3Q24 earnings (10/17) by assessing four scenarios.... More

Elevance Health (ELV) October 485 straddle priced into quarter results

Elevance Health (NYSE: ELV) October 485 straddle priced for a move of 5.5% into the expected release of quarter results before the bell on October 17.